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SUMMARY 
Objectives: To investigate the clinical manifestations 
and factors associated with mortality in patients with 
extrapulmonary tuberculosis (EPTB) at the Korle-Bu 
Teaching Hospital Chest Clinic in Accra, Ghana. 
Design: We conducted a retrospective chart review of 
patients treated for EPTB at the Chest Clinic between 
January 1, 2009 and December 31, 2011. Patients with 
a new diagnosis of EPTB without concomitant pulmo-
nary disease, aged 18 years or older, and who were 
treated at the Chest Clinic were eligible for participa-
tion in the study. Relevant data were abstracted from 
medical records and entered into a database. The fac-
tors associated with mortality were examined using 
bivariate and multivariate analysis. 
Results: Of the 157 patients in the study, the most af-
fected age group was 25-34 years old (33.1%), 57.3% 
were male, and 71 (55.5%) of the 128 patients tested 
for HIV were sero-positive.  Overall, 62 (39.5%) died 
during EPTB treatment. Mortality was associated with 
disseminated TB (AOR 149.85; P < 0.001), TB menin-
gitis (AOR 79.14; P < 0.001), abdominal TB (AOR 
23.59; P = 0.011), pleural effusion (AOR 12.6; P = 
0.021) and age (AOR 1.05; P = 0.021). Among HIV 
co-infected patients, early initiation of ART reduced 
mortality rate. 
Conclusions:  The site of EPTB was a key determinant 
of mortality. Given that death occurs soon after diagno-
sis, patients with suspected TB meningitis, disseminat-
ed, abdominal and pleural TB should be targeted for 
early diagnosis and treatment to reduce the high EPTB 
mortality in our setting.  
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Tuberculosis (TB) is the second leading cause of death 
due to an infectious disease worldwide.1 An estimated 
8.6 million new cases of tuberculosis (TB) were diag-
nosed in 2012 and 1.3 million died as a result of the 
disease, 0.3 million of whom were HIV positive TB 
patients.1 Despite declining rates of TB incidence and 
mortality worldwide, the proportion of extra-
pulmonary tuberculosis (EPTB) cases has increased.2-8 
Extrapulmonary tuberculosis accounts for more than 
20% of TB cases in the United States and Europe.9 
Inhalation of Mycobacterium tuberculosis infects the 
pulmonary system, but can infect any organ system 
via lympho-hematogenous dissemination.2, 10 There are 
multiple forms of EPTB, including pleural TB and 
lymphatic TB most commonly, as well as abdominal 
TB, meningeal TB, skeletal TB, and pericardial TB.3, 4, 
7, 11-13 The lymphatic, and meningeal forms of TB have 
a higher incidence in non-Caucasians.14 
 
Extrapulmonary TB cases have increased more than 
ten-fold in seven years in Ghana, from 109 new cases 
reported in 1995 to 1,301 new cases reported in 2012.1 
It is widely reported that EPTB occurs more frequently 
in immunocompromised patients.8, 15, 16 EPTB accounts 
for more than 50% of tuberculosis cases in HIV/AIDS 
patients as compared to 15-20% of TB cases in immu-
nocompetent patients.10, 17 In fact, EPTB is considered 
an AIDS defining disease.18 HIV co-infection is associ-
ated with more severe forms of EPTB, such as dissem-
inated and meningeal TB, and a higher risk of death.19 
Studies have shown that patients with EPTB tend to 
deteriorate more rapidly and have higher mortality 
rates as compared to patients with pulmonary TB.4, 20 
 
In a previous study on outcomes of TB patients, we 
found that TB meningitis and disseminated disease 
were significantly associated with death in the multi-
variate analysis.21  
 
 







Given the relatively small proportion of EPTB (37%) 
in our previous study, we were not able to adequately 
assess the risk of death due to other forms of EPTB or 
the clinical characteristics associated with death.  
 
In this study, we sought to identify the characteristics 
of patients with EPTB that are associated with in-
creased risk of death. Such data is needed to inform the 
design of focused strategies to improve the outcome of 
EPTB among those at highest risk of death.   
 
METHODS 
Patients aged 18 years or older who were newly diag-
nosed with EPTB at the Korle-Bu Hospital between 
January 1, 2009 and December 31, 2011 were eligible 
for participation in the study. Exclusion criteria includ-
ed age younger than 18 years old, transferring out to 
other DOTS centers before treatment completion, and 
concomitant pulmonary TB. WHO guidelines classify 
patients with concomitant pulmonary TB and EPTB as 
pulmonary TB (PTB), and consequently these patients 
were excluded from our study.1  
 
Patients receiving Category II treatment, defined as the 
retreatment of TB patients with first line medications, 
were also excluded.22 Patients who had their treatment 
interrupted for two consecutive months or more were 
defined as “lost to follow-up” in accordance with 
WHO guidelines.1 The Institutional Review Boards of 
Brown University and University of Ghana Medical 
School for human subjects reviewed and approved this 
study.  We performed a retrospective study using med-
ical records from the Korle-Bu Hospital Chest Clinic. 
A chart abstraction form was used to collect data such 
as age, sex, date of presentation and death, clinical fea-
tures, diagnostic tests performed, sites of EPTB, 
weight, and height.  For HIV-infected patients, infor-
mation such as the CD4 cell count was abstracted from 
TB medical records and from Korle-Bu HIV clinic 
records.  
 
EPTB cases were defined based on the World Health 
Organization (WHO) criteria.1 EPTB patients were 
identified based their medical charts, which indicated 
whether the patient had a diagnosis of EPTB or pulmo-
nary TB. A screening HIV test was performed using 
HIV 1-2 Stat-Pak® (Alere) and if positive, a confirma-
tory test was performed using OraQuick® ADVANCE 
Rapid HIV-1/2 antibody test. The Korle-Bu Teaching 
Hospital in Accra, Ghana, serves as a tertiary referral 
hospital for the surrounding urban community. Tuber-
culosis treatment consisted of two months of isoniazid, 
rifampin, ethambutol and pyrazinamide and four to ten 
months of isoniazid and rifampin depending on the site 
of TB infection. Patients with TB meningitis typically 
receive a 12 months course. The Ghana NTP treatment 
guidelines modified and published in 2012 recommend 
9 to 12 months treatment for neurological disease and 
pulmonary TB with large cavities, in line with WHO 
guidelines.23, 24 In Korle Bu Teaching Hospital, being a 
tertiary treatment centre, the NTP policy was extended 
to include spinal TB, and bone and joint TB for a min-
imum of 9 or a maximum of 12 months, co-managing 
with orthopaedic surgeons, who monitored for signs of 
resolution.  All other forms of EPTB were treated for 
six months. 
 
Patients who died during EPTB treatment were classi-
fied as “cases with mortality” and those who survived 
for the duration of the EPTB treatment were classified 
as “controls.”  Mortality was defined as death due to 
any cause during TB treatment because the cause of 
death in patients was not recorded in the medical rec-
ords. Data were entered into a Microsoft Excel data-
base and analysis was performed using STATA soft-
ware, R, and SAS 9.3.  Bivariate analysis of Student’s t 
test and Mann Whitney U test for continuous variables 
and chi-square test for categorical variables were used 
to explore the marginal relationship between predictors 
and death status. Bivariate analysis was used to assess 
the marginal effect of EPTB sites on outcome.  
 
Reference groups used in bivariate analysis were the 
condition states as compared to the non-condition 
states. Multivariate analysis with variable selection was 
used to assess its conditional marginal effects if EPTB 
sites were selected. Identification of potential risk fac-
tors for all-cause mortality was performed using lo-
gistic regression analysis to explore the joint effects of 
predictors on death status using the subjects’ infor-
mation. The Minimax Concave Penalty (MCP) variable 
selection method was used to select the predictors that 
had significant effects on death status.25, 26 All statisti-




During the study period, 580 patients were diagnosed 
with EPTB with or without concomitant pulmonary 
disease. Of these, 164 patients who transferred out to 
other treatment centers, 39 patients younger than 18 
years old, 33 patients who were lost to follow-up, and 
two Category II patients were all excluded from the 
study. In addition, 185 patients who had concomitant 
pulmonary tuberculosis were excluded. The final anal-
ysis included 157 patients with EPTB only.  Of the 157 
patients, the majority of patients (33.12%) were 25-34 
years old and 57.32% were male.  
 
 







The common forms of disease included disseminated 
TB (26.75%), bone/spine/joint TB (22.93%) and TB 
meningitis (19.11%)  
 
Table 1 Baseline characteristics of 157 patients with 
extrapulmonary tuberculosis who were treated at the 
Korle-Bu Teaching Hospital Chest Clinic in Accra, 
Ghana from 2009-2011 
Characteristic Number Percent 
Age (years) 
  18-24 21 13.38 
 25-34 52 33.12 
 35-44 36 22.93 
 45-54 30 19.11 
 55-65 11 7.01 
 ≥65 7 4.46 
Gender 
  Male 90 57.32 
 Female 67 42.68 
Body Weight (kg) at Start of Treatment 
 25-39 14 8.92 
 40-54 66 42.04 
 >=55 73 46.50 
Unknown 4 2.54 
HIV status  
  Positive 71 45.22 
 Negative 57 36.31 
 Unknown 29 18.47 
Site of extrapulmonary tuberculosis 
  Pleural TB 11 7.01 
TB Meningitis 30 19.11 
Bone/spine/joint TB 36 22.93 
Disseminated TB  42 26.75 
Abdominal TB 8 5.10 
Lymphatic TB 18 11.46 
Pericardial TB 3 1.91 
Other 9 5.73 
Treatment Outcome 
Completed 95 60.51 
Died 62 39.49 
 
Of the 157 patients included in the final analysis, 128 
(81.5%) had HIV test results available, of whom 71 
(55.5%) were seropositive. Among HIV positive pa-
tients, the median CD4 count was 90 cells/microliter 
(interquartile range (IQR) 25.0 – 241.0). Ten HIV co-
infected patients were already on ART a median of 
53.5 days (IQR 14.0 – 108.0) prior to TB. Twelve pa-
tients started ART while on TB therapy and 49 never 
received ART. The median time to ART initiation after 
starting TB treatment among the twelve patients was 
39.5 days (IQR 25.0 – 66.5). 
 
For patients who completed TB therapy, they complet-
ed treatment in a mean of 223.0 days made up of a 
mean of 9 or 12 months for TB meningitis and 
bone/joint/spine TB, and 6 months treatment for other 
forms of EPTB.  
The median (IQR) time to death among patients who 
died during treatment was 6 (3.0 – 25.0) days.  
 
Factors associated with treatment outcome 
Overall, 62 patients (39.49%) died while receiving 
EPTB treatment. The demographic and clinical features 
of the patients who died compared to those who com-
pleted therapy are shown in Table 2.  
 
Table 2 Bivariate analysis of factors associated with 
death compared to cured or completed therapy 
Characteristic Dead (N=62) Completed (N=95) P value 
Median (IQR) age  39.0 (30.0-46.0) 34.0 (26.0-48.0) 0.424 
Median (IQR) weight  50.0 (40.0-56.0) 55.4 (50.0-69.0) <0.000
1 
 N (%) N (%)  
Age   0.1044 
18-24 4 (19.0) 17 (81.0)  
25-34 18 (34.6) 34 (65.4)  
35-44 20 (55.6) 16 (44.4)  
45-54 14 (46.7) 16 (53.3)  
55-65 4 (36.4) 7 (63.6)  
≥65 2 (28.6) 5 (71.4)  
Gender   0.6109 
Male 34 (37.8) 56 (62.2)  
Female 28 (41.8) 39 (58.2)  
Night sweatsa    
Yes 0 (0) 3 (100)  
No 62 (40.3) 92 (59.7)  
Fever   0.1479 
Yes 9 (56.2) 7 (43.8)  
No 53 (37.6) 88 (62.4)  
Cough   0.2296 
Yes 9 (52.9) 8 (47.1)  
No 53 (37.9) 87 (62.1)  
HIV sero-positive   < 0.001 
Yes 46 (64.8) 25 (35.2)  
No 8 (14.0) 49 (86.0)  
Unknown 8 (27.6) 21 (72.4)  
Pleural TB   0.3900 
 Yes 3 (27.3) 8 (72.7)  
 No 59 (40.4) 87 (59.6)  
TB meningitis   <0.001 
 Yes 20 (66.7) 10 (33.3)  
 No 42 (33.1) 85 (66.9)  
Bone/spine/joint TB   <0.001 
 Yes 2 (5.6) 34 (94.4)  
 No 60 (49.6) 61 (50.4)  
Disseminated TB   <0.001 
 Yes 33 (78.6) 9 (21.4)  
 No 29 (25.2) 86 (74.8)  
Lymphatic TB   0.0089 
 Yes 2 (11.1) 16 (88.9)  
 No 60 (43.2) 79 (56.8)  
Abdominal TB   0.3894 
 Yes 2 (25.0) 6 (75.0)  
 No 60 (40.3) 89 (59.7)  
Pericardial TBa    
 Yes 0 (0.0) 3 (100.0)  
 No 62 (40.3) 92 (59.7)  
a P-values for night sweat symptom and for pericardial TB infection 
are not available given the low sample size for these two variables. 
 
 







The bivariate analysis revealed that patients who died 
were more likely to have disseminated TB, TB menin-
gitis, and to have HIV coinfection (Table 2). Those 
with lymphatic TB and bone/spine/joint TB were less 
likely to die (Table 2).  
 
In the multivariate model (Table 3), the sites of EPTB 
associated with death were disseminated TB (adjusted 
odds ratio (AOR) 149.85, 95% confidence interval (CI) 
19.44 – > 999.99; P < 0.001), TB meningitis (AOR 
79.14, 95% CI 11.01 – 568.97; P < 0.001), and ab-
dominal TB (AOR 23.59, 95% CI 2.05 – 271.54; P = 
0.0282). Other characteristics associated with mortality 
in multivariate analysis included age as a continuous 
variable in years (AOR 1.05, 95% CI 1.01 – 1.09; P = 
0.021) and pleural effusion (AOR 12.6, 95% CI 1.46 – 
109.32; P = 0.021).  
 
Table 3 Multivariate analysis of factors associated with 
mortality in EPTB patients at a the Korle-Bu Chest 
Clinic in Ghana  
Risk factor Odds ratio 95% CI P value 
Age  1.05 1.01 – 1.10 0.021 
    
HIV sero-negative 
versus unknown 
0.33 0.07 – 1.58 0.063 
HIV sero-positive 
versus unknown 
1.03 0.24 – 4.46 0.294 
Pleural Effusion 
(Yes vs. No) 
12.6 1.46 – 109.32 0.021 
Abdominal  (Yes 
vs. No) 
23.59 2.05 – 271.54 0.011 
TB meningitis  
(Yes vs. No) 




(Yes vs. No) 
8.96 0.86 – 93.78 0.067 
Disseminated TB 
(Yes vs. No) 




Patients with TB meningitis and disseminated TB (i.e. 
disease sites that were associated with high risk of 
death) compared to those with all other forms of EPTB 
were more likely to be HIV positive (77.8% vs. 17.6%, 
P <0.0001).  History of cough and fever as well as time 
between TB diagnosis and HIV testing, and time be-
tween TB diagnosis and TB treatment initiation were 
similar in the two groups (P > 0.05).     
Among HIV-infected patients, the mortality rate was 
highest in patients who never started ART, followed by 
patients who started ART before EPTB diagnosis and 
treatment, and lowest in patients who started ART after 
starting EPTB treatment (79.2% vs. 54.5% vs. 16.7% 
respectively; P <0.0002). In HIV co-infected EPTB 
patients, sites of EPTB infection associated with an 
increased risk of death were TB meningitis (AOR 8.0, 
95% CI 1.69 – 37.95; P = 0.0088), and disseminated 
TB (AOR 18.0, 95% CI 3.84 – 84.28; P = 0.0002).  
DISCUSSION 
This study investigated factors associated with mortali-
ty in a cohort of patients with EPTB who received 
treatment at a teaching hospital clinic in Accra, Ghana. 
Many previous studies on EPTB have focused on char-
acteristics of EPTB patients while few have looked at 
what predicts death in this population. The current 
study reports the predictors of mortality in all patients 
with EPTB as well as in those with HIV coinfection. 
Increasing age, TB meningitis, as well as disseminated, 
abdominal, and pleural TB disease were independent 
factors associated with increased risk of mortality.  
 
The higher risk of death in our study among patients 
with disseminated TB and TB meningitis is consistent 
with prior studies.4, 21, 27 In our cohort, patients with 
these severe forms of EPTB were more likely to have 
HIV coinfection.  HIV coinfection likely increased the 
risk of severe disease and death because of immuno-
suppression and delay in starting ART. Cases of EPTB, 
especially the severe forms of EPTB, are more often 
associated with a delayed diagnosis or are even missed 
completely and diagnosed at death.7, 12, 28  
 
Age over 40 years old, weight, and immunocompro-
mised states have been associated with mortality and 
may predispose patients to more serious forms of 
EPTB.19, 27, 29-31 A high index of clinical suspicion 
needs to be employed in order to detect EPTB early 
given that the presentation may be non-specific.12, 13, 32 
In our study, death occurred within a median of six 
days after diagnosis, which underscores the need for 
early diagnosis and empiric therapy. Patients with lym-
phatic system, bone, joint, or spine TB were less likely 
to die likely because of less severe disease or early 
recognition and therapy. 
 
HIV infection is an important factor associated with 
increased mortality in TB patients.  In our study, 65% 
of HIV co-infected EPTB patients died before complet-
ing TB treatment, while only 18.6% of HIV negative 
EPTB patients died.  
Severe forms of EPTB (meningeal and disseminated) 
were more likely to occur in the HIV-infected patients 
in our study, which is consistent with previous 
studies.3, 4, 19, 29, 30 Low CD4 counts in EPTB patients 
co-infected with HIV have also been shown to increase 
risk of disseminated or meningeal forms of TB.19, 32  
 
HIV patients who never started ART had a higher risk 
of death compared to those who started ART either 
before or after starting EPTB treatment, illustrating the 











Our study showed that nearly four out of five HIV-
infected patients with EPTB who never started ART 
died as compared to one out of every six who started 
ART after starting EPTB treatment or just over 
half who started ART before EPTB treatment, illustrat-
ing the importance of initiating ART in HIV coinfected 
patients. Overall, 49 (80%) of the 61 patients who were 
not on ART at the time of EPTB diagnosis never initi-
ated ART during TB treatment. While we could not 
evaluate the reasons for the delays in initiating ART in 
the study patients, all patients should have initiated 
ART during TB treatment.  
 
The WHO currently recommends that ART be initiated 
irrespective of CD4 cell count for all people with HIV 
and active TB.33, 34 TB treatment should be started first, 
followed by ART as soon as possible and within the 
first 8 weeks of starting TB treatment.34 The associa-
tion between older age and increased risk of mortality 
is most likely because of age-associated immunosup-
pression and comorbid conditions. 
 
We recognize that our study has several limitations. 
First, because of costs and high patient numbers, cul-
tures for Mycobacterium tuberculosis are infrequently 
performed at Korle-Bu. Thus, the diagnosis of EPTB 
was clinical in most cases and not confirmed. The ret-
rospective nature of the study was associated with 
missing data including unknown HIV status for 29 pa-
tients with ETPB. This could have affected the rela-
tionship between death and HIV status. Additionally, 
the exclusion of patients that were referred out or lost 
to follow-up makes overstatement of mortality more 
likely. Our findings may be less generalizable because 
we only studied patients seen at an urban center teach-
ing hospital and therefore have more severe or compli-
cated disease.  
 
CONCLUSION 
The mortality rate of EPTB in our study population 
was high and site of disease including TB meningitis 
and disseminated disease were the main determinants 
of death. Our data suggest that death occurs early in a 
majority of the patients at risk of death with EPTB, 
underscoring the need for rapid diagnosis and treatment 
in some of these patients. While the site of disease is 
not modifiable at presentation, early diagnosis and 
therapy of these severe forms of EPTB will be neces-
sary to reduce mortality. In addition, the early use of 
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